Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"California Institute of Regenerative Medicine","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Juvena Therapeutics Awarded Highly Competitive CIRM Grant To Advance Lead Program, JUV-161, To Treat Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","amount":"$41.0 million","upfrontCash":"Undisclosed","newsHeadline":"Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Juvena Therapeutics

    Menu

    Juvena Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Juvena Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1

              Details:

              JUV-161, which was identified by Juvena’s AI-driven drug discovery and development platform, has demonstrated an ability to restore muscle fiber formation, counter muscle atrophy & enhance muscle strength. It is being evaluated in preclinical studies for the treatment of DM1.

              Lead Product(s): JUV-161

              Therapeutic Area: Genetic Disease Product Name: JUV-161

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 23, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Juvena Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

              Details:

              JUV-161 is the only protein-based therapeutic being developed for a rare muscle-wasting disease, myotonic dystrophy type 1 (DM1).

              Lead Product(s): JUV-161

              Therapeutic Area: Genetic Disease Product Name: JUV-161

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Mubadala Capital

              Deal Size: $41.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing November 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Juvena Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Juvena Therapeutics Awarded Highly Competitive CIRM Grant To Advance Lead Program, JUV-161, To Treat Myotonic Dystrophy Type 1

              Details:

              The grant will fund the advancement of Juvena's lead program, fusion protein therapeutic JUV-161, for the treatment of the rare muscle-wasting disease, DM1, through initial IND-enabling studies and a pre-IND FDA meeting in the next 12-16 months.

              Lead Product(s): JUV-161

              Therapeutic Area: Genetic Disease Product Name: JUV-161

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: California Institute of Regenerative Medicine

              Deal Size: $3.9 million Upfront Cash: Undisclosed

              Deal Type: Funding February 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY